Document Detail

Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model.
MedLine Citation:
PMID:  25395213     Owner:  NLM     Status:  Publisher    
Inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, are characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Tessália Diniz Luerce Saraiva; Kátia Morais; Vanessa Bastos Pereira; Marcela de Azevedo; Clarissa Santos Rocha; Camila Castro Prosperi; Ana Cristina Gomes-Santos; Luis Bermudez-Humaran; Ana Maria Caetano Faria; Hervé M Blottiere; Philippe Langella; Anderson Miyoshi; Alejandra de Moreno de LeBlanc; Jean Guy LeBlanc; Vasco Azevedo
Related Documents :
23674053 - Bdnf-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.
9498233 - (-)deprenyl (selegiline), a catecholaminergic activity enhancer (cae) substance acting ...
17169103 - Infectious haemolytic anaemia causes jaundice outbreaks in seawater-cultured coho salmo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-13
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  -     ISSN:  1873-4316     ISO Abbreviation:  Curr Pharm Biotechnol     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-14     Completed Date:  -     Revised Date:  2014-11-15    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Extracellular Production of the Oncolytic Enzyme, L-Asparaginase, by Newly Isolated Streptomyces sp....
Next Document:  Encapsulation of Chondrocytes in High-Stiffness Agarose Microenvironments for In Vitro Modeling of O...